|
3.1 Tabac
|
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.9.1 AACR - sein
|
|
|
|
|
5.9.4 AACR - poumon
|
|
|
|
5.9.5 AACR - T-cell immunothérapies
|
|
|
|
|
5.9.7 AACR - divers
|
|
|
AACR 2016: CRISPR as a Screening Tool for Drug Targets [GEN]
|
|
|
|
|
|
In
one of the major symposiums at AACR—titled CRISPR in Drug Discovery—a
group of investigators presented data that showed how the genome editing
technology could be employed as a screening tool for identifying or
validating druggable cancer genes.
|
|
|
|
|
|
|
|
|
Noninvasive Test Detected Colorectal Cancer in Previously Unscreened Patients [AACR]
|
|
|
|
|
|
“We
were interested to see whether the ‘real-life’ experience with
Cologuard in clinical practice would be similar to the results seen in
the clinical trial,” Prince said. The patients’ clinicians offered
Cologuard screening to patients who had not had a colonoscopy screening
in 10 or more years, or a fecal occult blood test in a year or more.
|
|
|
|
|
|
|
|
5.9.9 AACR - immunothérapies
|
|
|
|
|
Nivolumab Improved Survival For Patients With Head and Neck Squamous Cell Carcinoma [AACR]
|
|
|
|
|
|
CheckMate-141
was a randomized, phase III clinical trial designed to determine
whether the PD-1 inhibitor nivolumab could extend overall survival for
patients with platinum-refractory recurrent or metastatic head and neck
squamous cell carcinoma compared with treatment of the investigator’s
choice, which was any of the commonly used therapeutics docetaxel,
methotrexate, or cetuximab.
|
|
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10 Politiques
|
|
|
Windfall for cancer research sets off a scramble for clout [STAT]
|
|
|
|
|
|
“If
it was the brain cancer doctors, it was ‘We deserve more than you do.’
The prostate guys, ovarian cancer, every group focusing on a particular
piece of cancer felt that they should be getting more of the money, and
that there was money going to others that they could do something better
with.”
|
|
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.9 Controverses
|
|
|
|